Previous 10 | Next 10 |
2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting 100% (19/19) patients achieved minimal residual disease negative stringent complete response (MRD- sCR)...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for th...
2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...
2023-09-21 16:52:03 ET Summary Gracell Biotechnologies is a China-based biotech focused on next-generation cell therapies for hematologic malignancies. Their CAR T platforms aim to address manufacturing time and T cell exhaustion issues seen in currently approved therapies. Th...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for th...
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , ...
2023-08-14 11:40:24 ET Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Conference Call August 14, 2023, 08:00 AM ET Company Participants William Cao - Chairman, Chief Executive Officer Wendy Li - Chief Medical Officer Kevin Xie - Chief Financial Officer ...
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portion Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in...
2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...